Abstract: The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.
Type:
Application
Filed:
August 23, 2004
Publication date:
April 14, 2005
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Thomas Piccariello
Abstract: A pharmaceutical composition comprising an active agent bound to a scaffold for dendritic encapsulation wherein said scaffold is covalently or non-covalently attached to a polysaccharide. More specifically, the invention is directed to active agent complexes or conjugates which utilize dendritic encapsulation alone or in combination with other delivery systems to improve and target active agent release.
Type:
Application
Filed:
July 8, 2004
Publication date:
March 31, 2005
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Thomas Piccariello, Travis Mickle, Barney Bishop
Abstract: The present invention provides compositions and methods to decrease inter-patient variability particularly with respect to the systemic concentration of a drug. More particularly the invention relates to oral drugs which are conjugated to peptides or related carriers which alter release characteristics as compared to the analogous free drug.
Abstract: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Type:
Application
Filed:
June 1, 2004
Publication date:
February 17, 2005
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello
Abstract: A composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for delivery of an active agent to a patient comprising administering to the patient a composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for protecting an active agent from degradation comprising covalently attaching the active agent to a polypeptide. Also provided is a method for controlling release of an active agent from a composition comprising covalently attaching the active agent to the polypeptide.
Type:
Application
Filed:
December 5, 2003
Publication date:
July 1, 2004
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Thomas Piccariello, Lawrence P. Olon, Randall J. Kirk
Abstract: Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism and depression. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.
Type:
Application
Filed:
July 31, 2003
Publication date:
June 17, 2004
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Thomas Piccariello, Anne-Frederique Le Clercq
Abstract: The present invention relates to compositions comprising an active agent. More specifically, the invention relates to active agent compositions that include a peptide carrier and an active agent covalently attached to at least one of the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain; methods for protecting and administering active agents; and methods for treating thyroid disorders.
Type:
Application
Filed:
May 2, 2002
Publication date:
May 6, 2004
Applicant:
New River Pharmaceuticals, Inc.
Inventors:
Thomas Piccariello, Lawrence Peter Olon, Alex Saunders Goldstein, James Scott Moncrief, Nancy Johnston Boerth
Abstract: A composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for delivery of an active agent to a patient comprising administering to the patient a composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for protecting an active agent from degradation comprising covalently attaching the active agent to a polypeptide. Also provided is a method for controlling release of an active agent from a composition comprising covalently attaching the active agent to the polypeptide.
Type:
Grant
Filed:
August 22, 2000
Date of Patent:
April 6, 2004
Assignee:
New River Pharmaceuticals Inc.
Inventors:
Thomas Piccariello, Lawrence P. Olon, Randall J. Kirk
Abstract: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.
Type:
Application
Filed:
May 29, 2002
Publication date:
April 1, 2004
Applicant:
New River Pharmaceuticals Inc.
Inventors:
Thomas Piccariello, Randal J. Kirk, Lawrence P. Olon
Abstract: Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.